Y.B Urban Renewal - Residential Development LTD
CSURE-M | TA
Overview
Corporate Details
- ISIN(s):
- IL0001110134
- LEI:
- Country:
- Israel
- Address:
- 2 Hahadarim Street, 7712102 Ashdod
- Website:
- https://www.yb-i.co.il/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Cannassure-M focuses on the development and production of medical cannabis products in Israel.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-15 19:43 |
Regulatory Filings
Trading in the company's shares (ISIN IL0001110134) will be renewed on Monday, …
|
Hebrew (modern) | 113.5 KB | ||
| 2025-05-05 15:53 |
Regulatory Filings
The securities not included in the Illiquid list as of May 4th
2025 due to mar…
|
Hebrew (modern) | 217.1 KB | ||
| 2025-05-05 11:32 |
Regulatory Filings
Suspension of trading due to failure in publication of financial reports s for …
|
Hebrew (modern) | 79.7 KB | ||
| 2025-04-28 18:40 |
Regulatory Filings
Securities that have joined the program and the Market Makers that will operate…
|
Hebrew (modern) | 366.8 KB | ||
| 2025-04-20 18:21 |
Regulatory Filings
Failure in publishing financial reports-Notification
|
Hebrew (modern) | 128.0 KB | ||
| 2025-03-06 18:39 |
Regulatory Filings
Illiquid Candidates securities list as of May 4th 2025
|
Hebrew (modern) | 245.6 KB | ||
| 2024-07-28 18:05 |
Regulatory Filings
The company's securities will be transferred from the maintenance list to the m…
|
Hebrew (modern) | 106.5 KB | ||
| 2024-07-11 17:14 |
Regulatory Filings
Changes in the company's share symbol correction: YBRD-M
|
Hebrew (modern) | 104.0 KB | ||
| 2024-07-09 17:01 |
Regulatory Filings
Changes in the company's name and security, effective as of July 11, 2024
|
Hebrew (modern) | 105.9 KB | ||
| 2024-06-25 19:48 |
Regulatory Filings
Changes in Sector Classification of Listed Companies as of Sunday, June 30, 2024
|
Hebrew (modern) | 135.9 KB | ||
| 2024-03-21 18:45 |
Regulatory Filings
Will trade on Monday March 25 2024, with unlimited price fluctuation at the ope…
|
Hebrew (modern) | 137.2 KB | ||
| 2023-07-13 20:43 |
Regulatory Filings
Transfer to the Maintenance List on July 17, 2023
|
Hebrew (modern) | 149.7 KB | ||
| 2023-07-03 19:48 |
Regulatory Filings
Companies that do not comply with the Maintenance Rules and are candidates to b…
|
Hebrew (modern) | 116.3 KB | ||
| 2023-01-15 17:37 |
Regulatory Filings
Non-Compliance with the Maintenance Rules Based on Data as of December 31, 2022…
|
Hebrew (modern) | 132.9 KB | ||
| 2021-01-07 15:45 |
Regulatory Filings
On Sunday, 10 January 2021, trading will commence in the following Security: CA…
|
Hebrew (modern) | 186.1 KB |
Automate Your Workflow. Get a real-time feed of all Y.B Urban Renewal - Residential Development LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Y.B Urban Renewal - Residential Development LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Y.B Urban Renewal - Residential Development LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
United States of America
ANL
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
United States of America
ADMA
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
United States of America
ADVM
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
France
ALDVI
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Sweden
AEGIR
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
France
AELIS
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
United States of America
AEON
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
Japan
2927
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
United States of America
AGEN
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO
United States of America
AGIO